Analgin-Rusphar (Sodium Metamizole) is commonly used in areas where short-term symptom management is appropriate, particularly in clinical settings marked by increased discomfort or tension. Metamizole-containing medicines are used for treating symptoms related to physical discomfort and systemic imbalance, such as moderate to severe pain and fever. It is relevant in contexts marked by increased discomfort or tension, applied across domains that involve a combination of symptoms associated with acute or episodic changes, including pain after trauma or surgery, severe headaches, and discomfort associated with certain chronic conditions.

The medication is applied when appropriate across domains involving significant symptom expression. It may be part of symptomatic management to help address symptoms related to acute discomfort, support the management of fever, and ease symptoms linked to episodic spasms, such as those associated with renal or biliary colic. This support assists with maintaining a sense of stability when symptoms are more noticeable, helping ease the overall symptom burden.

---

Quick Fact: Relief for Pain and Fever Analgin-Rusphar is applied when symptoms create noticeable physiological strain, specifically for managing pain of moderate to severe intensity and supporting the management of persistent high fever.

Analgin-Rusphar, containing metamizole sodium, is an analgesic and antipyretic drug primarily indicated for the treatment of acute severe pain and high fever that has proven unresponsive to other therapeutic options. It may be used for pain following surgery or injury, as well as pain associated with colic or tumors.

---

Contraindications (Who Cannot Use)

Analgin-Rusphar is not recommended for a significant number of individuals due to the risk of severe, though rare, side effects, particularly agranulocytosis (a severe reduction in white blood cells). Key contraindications include:

• Hypersensitivity or allergy to metamizole, other pyrazolones (like phenazone, propyphenazone), or pyrazolidines.
• A history of analgesic-induced asthma, urticaria, or angioedema after taking pain relievers like salicylates (aspirin), acetaminophen, or NSAIDs.
• Conditions associated with impaired bone marrow function or the formation of blood elements, such as agranulocytosis, neutropenia, or aplastic anemia.
• Certain hereditary metabolic disorders, including acute intermittent hepatic porphyria or congenital glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• Pregnancy, particularly during the third trimester, and breastfeeding, as the drug's metabolites pass into breast milk.
• Infants under 3 months of age or weighing less than 5 kg.

---

Precautions (Use with Caution)

Caution is required, and a physician's advice is essential, for patients with existing kidney or liver impairment, hypotension (low blood pressure), or a history of cardiovascular diseases. Prolonged treatment requires regular blood cell count monitoring.

Interactions with other medicines and products

Analgin-Rusphar, containing Sodium Metamizole, has officially documented interactions primarily centered on enzyme induction and specific pharmacodynamic risks, as outlined in regulatory prescribing information.

Documented Interaction Patterns

Metamizole is recognized as a moderate to strong inducer of drug-metabolizing enzymes (CYP2B6, CYP3A4, CYP2C19). This mechanism leads to the accelerated clearance and subsequent reduction in plasma concentrations of various co-administered medicines, potentially lowering their efficacy. This effect is documented with drugs such as Cyclosporine, Tacrolimus, Bupropion, Efavirenz, Methadone, Valproate, and Sertraline.

Pharmacodynamic and Timing Constraints

Interacting Agent	Official Interaction Description	Regulatory Constraint
Acetylsalicylic Acid (low-dose)	Metamizole may reduce its antiplatelet effect.	Separation of administration time may be required.
Chlorpromazine	Increased risk of severe hypothermia.	Co-administration is to be approached with caution.
Alcohol (Ethanol)	Increased risk of an alcohol intolerance reaction.	Use is generally discouraged.

Combinations with other medicinal products known to cause agranulocytosis are typically restricted or contraindicated due to an additive risk for severe hematologic toxicity.

How Analgin-Rusphar Works

Analgin-Rusphar operates through a synergistic, multi-component pharmacodynamic mechanism that targets both the central processing of nociceptive signaling and the peripheral generation of involuntary smooth muscle contractility.

Central Modulation of Nociception and Thermal Regulation

Metamizole's active metabolites concentrate within the Central Nervous System (CNS). The primary mechanism involves the inhibition of Cyclooxygenase-3 (COX-3) and modulation of opioidergic and cannabinoid pathways. This action collectively reduces the flux of nociceptive signals and resets the hypothalamic set-point for thermal regulation, resulting in antipyresis.

Peripheral Modulation of Smooth Muscle Contractility

Two components provide coordinated peripheral relaxation of involuntary muscle tissue. Fenpiverinium acts as an antagonist at Muscarinic Acetylcholine Receptors ( mAChRs), blocking the nerve signals that drive contraction (neurogenic action). Simultaneously, Pitofenone directly interferes with the muscle's internal contraction mechanism by blocking Voltage-gated Calcium channels ( Ca^2+ channels) (myotropic action). This multi-target action causes a reduction in involuntary smooth muscle contractility.

Official Administration Guidelines for Analgin (Metamizole)

The official instructions for using Analgin (metamizole) detail the approved forms, routes, and dosing limits.

Administration Routes and Forms

Analgin is available for administration via several official routes, depending on the formulation:

• Oral Use: Tablets, capsules, or oral drops/solutions.
• Injection: Intramuscular (IM) or slow Intravenous (IV) injection/infusion.
• Rectal Use: Suppositories.

Official Dosing and Frequency

Administration must commence at the lowest recommended dose and only be increased if medically necessary.

Population	Single Dose (Maximum)	Frequency	Maximum Daily Dose
Adults (ge 15 years)	1,000 mg (Oral)	Up to 4 times daily	4,000 mg (Oral)
Pediatric (by weight)	8–16 mg per kg body weight	At intervals of 6–8 hours	Dose should not exceed 4,000 mg

Special Administration Conditions

• Pediatric Dosing: For children younger than 15 years, the dosage must be precisely calculated based on the child’s body weight in kg. Certain dosage forms may be unsuitable for smaller children due to fixed strength.
• Parenteral Administration: If administered intravenously (IV), the injection must be performed slowly. The total daily dose for injectable forms should not exceed 5,000 mg.
• Missed Dose: If a dose is missed, take the next scheduled dose as planned, maintaining the regular time interval. Do not double the dose.
• Timing: Oral forms can generally be taken with or without food.

Recent Clinical Evidence: Analgin-Rusphar

Research has explored the potential therapeutic use of Analgin-Rusphar (Metamizole) for managing acute pain and fever. Studies have investigated its use as a non-opioid option in various clinical settings.

Key Research Findings

A series of clinical trials evaluated measured changes in pain intensity, typically using the Visual Analog Scale (VAS), following surgical procedures and in cases of colic pain. These studies often focused on the drug’s use in single-dose administration.

• Post-Surgical Pain: Studies examined the effect of Analgin-Rusphar in the management of moderate to severe pain after various operations. Research reported on the observed pain assessment scores compared to placebo and certain other common analgesics.
• Colic Pain: Trials investigated its use in relieving visceral pain, particularly renal and biliary colic. These studies measured the proportion of patients requiring rescue medication and changes in pain scores over defined periods.

Safety and Pharmacovigilance Data

Studies evaluated the drug's safety profile, focusing on adverse events. The most commonly reported events included mild gastrointestinal upset and allergic reactions. The most severe, though rare, adverse effect reported in global pharmacovigilance data is agranulocytosis (a severe reduction in white blood cells), which requires monitoring in regions where the drug is frequently used. Research continues to investigate the incidence rate of this rare event across diverse patient populations. Findings regarding the drug's risk profile were reported in clinical studies, and regulatory assessments confirm its risk-benefit profile in approved markets.

Common questions about Analgin-Rusphar (FAQ)

---

Q: Can I take Analgin-Rusphar for a minor headache?

According to the official product information, Analgin-Rusphar is indicated for various pain syndromes, including headaches and toothaches. Its use is based on the specific conditions listed in the approved regulatory documents. Official product information lists specific conditions for which the drug is approved.

---

Q: Does Analgin-Rusphar contain an opioid or narcotic substance?

Regulatory documents state that Analgin-Rusphar contains metamizole sodium (analgin) as its active substance. Metamizole is classified as a non-opioid analgesic (pain reliever) and antipyretic (fever reducer). Regulatory documents confirm that the active substance, metamizole sodium, is classified as a non-opioid analgesic and antipyretic.

---

Q: How long does it take for Analgin-Rusphar to start working after I take it?

Official product information suggests that the analgesic (pain-relieving) effect of Analgin-Rusphar usually starts to manifest relatively quickly after administration. The actual onset time can vary between individuals, depending on factors like how the drug is administered and absorbed.

---

Q: Can I drink alcohol while taking Analgin-Rusphar?

Official product information cautions against the simultaneous use of Analgin-Rusphar and alcohol. The combination may lead to an increased risk of certain side effects or potentially alter the drug's effect, according to regulatory statements. Patients are advised to review the official product label regarding concurrent alcohol use.

---

Q: What is the maximum duration I can safely use Analgin-Rusphar?

The maximum duration for self-administration of this drug without medical supervision is specified in the official product documents. If continuous pain relief is required beyond the duration specified on the label, consulting a healthcare professional is necessary for ongoing monitoring and condition assessment.

---

Q: Is Analgin-Rusphar safe to take if I am currently pregnant?

Official information indicates that Analgin-Rusphar is contraindicated (should not be used) in patients who are pregnant, especially during the first and third trimesters. Official documentation indicates that Analgin-Rusphar is generally not recommended for use during pregnancy, as stated in the regulatory safety warnings.

---

Q: Can I use Analgin-Rusphar if I have a fever but no pain?

Analgin-Rusphar is officially classified as both an analgesic (pain reliever) and an antipyretic (fever reducer). Official sources confirm that its indications include management of elevated body temperature (fever). Therefore, it is indicated for reducing fever.

The storage and disposal of Analgin-Rusphar (metamizole sodium) are governed by specific regulatory requirements to ensure chemical stability and public safety.

Storage Requirements

Scope Requirement	Official Regulatory Statement
Labeled temperature	Store at a temperature below 25 C or 30 C.
Protection rules	Protect from light and store in a dry place.
Handling constraints	Do not freeze the medicine.
Container rules	Store in the original container and keep it tightly closed.
Child safety	Keep out of the sight and reach of children.
In-use stability	The injection solution must be used immediately after opening.

Disposal Requirements

The official labeling directs that the medicine must not be disposed of via household waste or wastewater. Individuals are instructed to ask the pharmacist how to dispose of unused or expired product to ensure it is managed through a proper pharmaceutical waste or take-back system.